α
AlphaSteve
← Theses
Pipeline · first-read only

RMD

ResMed Inc.
Health Care / Medical Devices
Shelve
No full thesis yet — this ticker is on the pipeline. Latest first-read: Jun 3, 2026.

ResMed — first-read 2026-06-03

1. Why it surfaced

ResMed hit a fresh 52-week low at $198.60 in late May 2026 T3(https://www.investing.com/news/company-news/resmed-stock-hits-52week-low-at-19860-amid-challenging-year-93CH-4716983) against a 52-week range of $180.27–$293.81 T3(https://www.tikr.com/blog/resmed-stock-is-down-22-in-2026-heres-why-analysts-still-sees-256-fair-value). The drawdown is 32–33% from the $294 high. The S&P 500 trefis screen of stocks at 52-week lows named ResMed alongside Boston Scientific as the two quality medical-device franchises trading at the lows T3(https://www.trefis.com/articles/600981/sp-500-stocks-trading-at-52-week-low-183/2026-06-02). The screen hit is the quality-business-at-52-week-low pattern from capital-cycle §"trough signals" and margin-of-safety-pricing §"buying at the trigger" — multi-quarter price compression at a franchise where historical ROIC has been comfortably above WACC. ResMed is a fresh discovery — no prior coverage in any scan, watchlist, or thesis through 2026-06-02 PM.

2. Business in a paragraph

ResMed sells medical devices and connected software for sleep-disordered breathing and respiratory care. The Sleep and Breathing Health segment ($1.26B in Q3 FY26, +11% YoY) ships CPAP, APAP, and bi-level positive-airway-pressure devices alongside the high-margin mask and accessory consumables that drive recurring revenue T1(https://www.stocktitan.net/sec-filings/RMD/8-k-resmed-inc-reports-material-event-a7c2bc9d09a4.html). The Residential Care Software segment ($171M in Q3 FY26, +6% YoY) sells the AirView and Brightree connected platforms that home-care providers use to manage 28 million patients and 20 billion nights of sleep data across its installed base T3(https://www.marketsandmarkets.com/ResearchInsight/sleep-apnea-devices-market.asp). ResMed holds an estimated 50–60% global market share in obstructive-sleep-apnea treatment and over 50% US share against Philips Respironics and Fisher & Paykel T3(https://portersfiveforce.com/blogs/competitors/resmed); the company holds 8,200 patents including 1,000+ on airflow technology and data algorithms. Q3 FY26 revenue rose 11% YoY (8% constant currency) to $1.43 billion; non-GAAP EPS rose 21% YoY to $2.86; non-GAAP gross margin expanded 290 bps YoY to 62.8% T1; T3(https://www.investing.com/news/company-news/resmed-q3-fy26-slides-margins-expand-digital-ecosystem-scales-93CH-4651682). Management announced the $340M Noctrix Health acquisition in late May, extending the franchise from sleep apnea into restless-leg-syndrome neuromodulation T3(https://www.fool.com.au/2026/05/01/resmed-reports-double-digit-revenue-and-profit-increases-in-q3-fy26/).

3. Back-of-envelope valuation

Scenario Normalized EPS basis EPV at 8% WACC Greenwald-modified (+3% perpetual growth) Current $198 MoS
Trough — GLP-1 erosion stays $9.50 (FY27 down 10% from $10.50 run-rate) ~$119 ~$190 EPV neg; Greenwald roughly flat
Normalized — current run-rate holds $11.50 (Q3 FY26 annualized) ~$144 ~$230 EPV −27%; Greenwald +16%
Recovery — Zepbound co-prescription expands TAM $13.00 (mid-single-digit grow on broader TAM) ~$163 ~$260 EPV −18%; Greenwald +31%

WACC assumption: 8% reflects ~4.5% nominal cost of debt (investment-grade balance sheet with modest net debt after Noctrix close), ~9.5% cost of equity (5.5% ERP plus 4% risk-free plus 0.8 beta), 75/25 equity/debt weighting; on a medical-device-franchise calibration the 8% is the upper end and 7% is defensible for a defensible-moat franchise with recurring-revenue scale AS-cal. The 7% WACC alone shifts the normalized EPV-only to ~$164, narrowing the EPV-only gap meaningfully.

The decision-relevant point is not the central value — Greenwald-modified at the normalized case is roughly $230, against $198 today, a 14% gap. The decision-relevant point is which valuation frame is the right one for this business. ResMed is a structurally growing franchise (high-single-digit revenue growth guidance reiterated through 2030 per management; Q3 FY26 +11% reported, +8% constant currency); the EPV-only frame mechanically understates value at any business that grows. But the EPV-only frame is the right downside floor for the deep-value-discipline question — what is this worth if growth stops? At $144 (8% WACC, no growth on the current run-rate) the EPV-only floor sits 27% below current. The shelve trigger at $170 represents a price at which the Greenwald-modified base case offers 35% upside to the central value and the EPV-only frame at 7% WACC offers a thin but real margin. At $198, the kit is paying for the GLP-1 thesis resolving favorably; at $170, the kit is paying meaningfully less for the same option.

4. The one thing that decides this

Does the GLP-1 weight-loss-drug cycle compress or expand ResMed's addressable obstructive-sleep-apnea population? The street has priced the bear case — that Zepbound, Wegovy, and Mounjaro shrink the OSA pool by reducing the obese-adult population for whom CPAP is indicated. The variant view, which sits inside contrarian-indicators, is that Eli Lilly's Zepbound is now FDA-approved specifically for OSA in BMI ≥30 patients and that the combination-of-care framing — Zepbound for weight management plus CPAP for residual airway-obstruction therapy — is being positioned by sleep-medicine clinical literature as the gold standard rather than as competition T3(https://sleepreviewmag.com/sleep-health/sleep-whole-body/weight/glp-1-medications-show-promise-first-drug-therapy-sleep-apnea/); T3(https://fnarena.com/index.php/2026/02/02/glp-1s-drive-strong-quarter-for-resmed/). Management's 1.7-million-patient analytical dataset suggests that GLP-1 adoption to date has not reduced CPAP adherence among the co-treated cohort T3(https://www.tikr.com/blog/resmed-stock-near-52-week-low-despite-21-eps-growth-heres-what-the-glp-1-data-actually-shows). The Q4 FY26 print in late July and the Q1 FY27 print in late October are the operative tests — device sales sustaining 8%+ constant-currency growth on the GLP-1-aware comp would falsify the TAM-compression thesis. The 11% Q3 FY26 print at +21% EPS growth and +290 bps margin expansion is the first operative data point on the variant view; the street has not repriced.

5. Top risk

The single largest reason this could be a value trap is patent-cliff-style competitive erosion from a successful Philips Respironics relaunch combined with a sustained GLP-1 TAM compression at the new-patient cohort. Philips' multi-year DreamStation recall removed roughly 15–20% of the US installed base from competitive contention; the cycle now turns the other way as Philips rebuilds and re-enters the market with a refreshed product line. If Philips captures 5–7 points of share back from ResMed over fiscal years 26–28 while GLP-1 medications reduce the new-patient diagnosis pipeline by mid-single-digit percentages annually for the next three years, ResMed's reported revenue growth compresses from the current 11% to flat or slightly negative, operating leverage reverses, and the recurring mask-and-supplies revenue continues to grow only at the run-off rate of the existing installed base. In that scenario the FY27 EPS prints flat-to-down rather than continuing the trajectory toward $12.50–$13.00, the Greenwald-modified frame stops being the right valuation frame, and the stock walks down toward the EPV-only floor at $140–$160. Net debt after the $340M Noctrix close is manageable but no longer the rock-solid net-cash position the franchise carried two years ago, narrowing the downside cushion if free-cash-flow conversion compresses simultaneously with revenue.

6. Decision

Shelve with trigger at $170.00, two-quarter horizon. ResMed is a structurally durable medical-device franchise with a 50–60% market share, an 8,200-patent technical moat, a 28-million-patient AirView software ecosystem driving switching costs, and a recurring mask-and-supplies revenue stream that anchors free-cash-flow conversion at high rates. The street's GLP-1 bear case has driven a 33% drawdown from the high; the variant view that Zepbound co-prescription expands rather than compresses the OSA TAM is supported by the Q3 FY26 print at 11% revenue / 21% EPS / 290 bps GM expansion. The kit's discipline holds — the EPV-only frame puts fair value at $144 at 8% WACC and $164 at 7%, and the Greenwald-modified base case at $230 requires the variant view to be right. At $198, the kit pays a meaningful premium to the EPV-only floor for the variant view. At $170, the kit pays roughly EPV-only fair value at 7% WACC for the franchise plus the Greenwald-modified upside as a free option. Refresh the first-read if (a) the stock hits $170 on no fundamental change, (b) Q4 FY26 prints with constant-currency device revenue sustaining 8%+ growth, or (c) a Philips DreamStation re-entry data point materially changes the competitive landscape. The trigger price sits below the $180.27 prior-year low — a print below that level would itself be the structural-discriminator event.

Sources

Linked